| NAME |
AFFILIATION |
| FOCUS GROUP 3 |
|
| Shannon Allen |
USAID |
| Ernest Asante-Appiah |
Merck, Sharpe & Dohme, LLC |
| Mark Baker |
ViiV Healthcare |
| Marc Baum |
Oak Crest Institute of Science |
| Paul Benn |
ViiV HC |
| Matthew Bosse |
Gilead |
| Su-Young Choi |
FDA |
| Robert Choy |
PATH |
| Vivian Cox |
Johnson & Johnson |
| Logan Donaldson |
The Forum for Collaborative Research |
| Lobna Gaayeb |
Medicines Patent Pool |
| Timothy Hallett |
Imperial College London |
| Craig Hendrix |
Johns Hopkins University |
| Walid Heneine |
CDC |
| Randolph Matthews |
Merck & Co, Inc; Medical Director |
| Antoinette Nelson |
USAID |
| Eric Nuermberger |
Johns Hopkins University |
| Adeniyi Olagunju |
University of Liverpool |
| Roger Ptak |
NIAID/DAIDS/TRP/DDPRB |
| Richard Scranton |
Lyndra Therapeutics |
| Raju Subramanian |
Gilead Sciences |
| Sijia Tao |
Emory University |
| David Thomas |
JHU |
| John Walker |
Bill & Melinda Gates Foundation |
| Andrew Weber |
ViiV Healthcare |
| Charles Wells |
Bill & Melinda Gates Medical Research Institute |
| Raymond Xu |
Otsuka |
